Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumor

Summarize

        Gastrointestinal stromal tumor (GIST) usually originates from the cells of the stomach wall or small intestinal wall. Gastrointestinal stromal tumor can be benign or malignant (cancer). Pediatric gastrointestinal stromal tumor is more common in girls and adolescents.

Epidemiological

 not have

Etiology & Risk Factors

The characteristics of gastrointestinal stromal tumors in children are significantly different from those in adults, and tumor gene mutation testing must be performed. A small number of pediatric patients have the same genetic mutations as adult patients.

Classification & Staging

 not have

Clinical Manifestations

The following genetic disorders may increase the risk of gastrointestinal stromal tumors:

50. Carney triad (commonly referred to as Carney triad): Suffering from pulmonary chondroma, gastrointestinal stromal cell tumor and paraganglioma. ​
50. Carney-Stratakis syndrome
50.         Most gastrointestinal stromal tumor children have tumors located in the stomach, and tumor bleeding leads to anemia. The signs and symptoms of anemia are as follows:

50. Feeling tired
50.  dizzy
50. Accelerated heart rate or arrhythmia
50. Breathing is short
50.  ochrodermia

        Gastrointestinal stromal tumor signs also include: abdominal mass or intestinal obstruction (abdominal spasmodic pain, nausea, vomiting, diarrhea, constipation, and bloating). Anemia caused by other conditions may also cause the same symptoms.

Clinical Department

 not have

Examination & Diagnosis

 not have

Clinical Management

For the treatment information below, see the treatment plan overview section above.

        Children with the same genetic mutation as adult patients were treated with targeted therapy with tyrosine kinase inhibitors.

        Children without genetic mutations can be exposed to the tumor through surgery.

        Children with recurrent gastrointestinal stromal tumors may be considered for clinical trials to test whether the genes in the patient's tumor samples have changed and to target the patient based on the type of gene change.

Prognosis

 not have

Follow-up & Review

 not have

Daily Care

 not have

Cutting-edge therapeutic and clinical Trials

 not have

References

 not have

Audit specialists

 not have